Contact Information:

Media Contact

Ed Hagen
edhagen@wsu.edu
360-546-9257

Twitter: WSUNews

http://www.wsu.edu




Kredyty mieszkaniowe Kredyty mieszkaniowe

Sprawdź aktualny ranking najlepszych kredytów mieszkaniowych w Polsce - atrakcyjne kredytowanie nieruchomości.

PRESS-NEWS.org - Press Release Distribution
FREE PRESS RELEASES DISTRIBUTION
RSS - Press News Release
Add Press Release

WSU researchers see link between hunter-gatherer cannabis use, fewer parasites

Study suggests unconscious use of 'medical marijuana'


2015-06-01
(Press-News.org) VANCOUVER, Wash.--Washington State University researchers have found that the more hunter-gatherers smoke cannabis, the less they are infected by intestinal worms. The link suggests that they may unconsciously be, in effect, smoking medical marijuana. Ed Hagen, a WSU Vancouver anthropologist, explored cannabis use among the Aka foragers to see if people away from the cultural and media influences of Western civilization might use plant toxins medicinally. "In the same way we have a taste for salt, we might have a taste for psychoactive plant toxins, because these things kill parasites," he said. In an earlier study, Hagen found that the heavier tobacco smokers among the Aka also had fewer helminths, parasitic intestinal worms. He cautions, however, that the studies have their limits. While nicotine has been seen killing worms in livestock, that hasn't been directly demonstrated in humans. Cannabis kills worms in a petri dish, but researchers have not shown it killing worms in animals, Hagen said. The Aka are a "pygmy" people of the Congo basin. As one of the world's last groups of hunter-gatherers, they offer anthropologists a window into a way of life accounting for some 99 percent of human history. They might also offer an alternative hypothesis to explain human drug use. The prevailing explanation is that recreational drugs "hijack the pleasure centers of the brain," making people feel good. But they also trigger mechanisms that tell us we're consuming something toxic, tasting bitter and making us feel sick. "So we thought, 'Why would so many people around the world be using plant toxins in this very 'recreational' way?" said Hagen. "If you look at non-human animals, they do the same thing, and what a lot of biologists think is they're doing it to kill parasites." The issue is significant on at least two fronts, write Hagen and his colleagues, with substance abuse and intestinal helminth infection being "two of the developing world's great health problems." Their study appears in the American Journal of Human Biology. Researchers are unsure when the Aka might have first smoked cannabis or when it arrived on the continent. It may have come with traders from the Indian subcontinent around the first century A.D., but Hagen and his colleagues say it might not have been smoked until European colonization in the 17th Century. Hagen surveyed almost all of the nearly 400 adult Aka along the Lobaye River in the Central African Republic and found roughly 70 percent of the men and 6 percent of the women used cannabis. The polling was supported by bioassays of the men that found high enough levels of THCA, a metabolic byproduct of cannabis's active ingredient, to indicate that 68 percent of them had recently smoked. Stool samples collected from the men to gauge their worm burden found some 95 percent of them were infected with helminths. But those who consumed cannabis had a significantly lower rate of infection. A year after being treated with a commercial antihelmintic, the cannabis users were reinfected with fewer worms. While the Aka deliberately consume a tea of a local plant, motunga, to fight parasitic infections, they do not think of cannabis or tobacco as medicine, Hagen said. This suggests they are unconsciously using cannabis to ward off parasites, he said.

INFORMATION:

Hagen's co-authors on the study are Casey Roulette, who did the research as part of his WSU PhD, and Pasteur Institute researchers Mirdad Kazanji and Sébastien Breurec.


ELSE PRESS RELEASES FROM THIS DATE:

Discovery could improve radiotherapy for wide range of cancers

2015-06-01
Cancer Research UK scientists have discovered how giving a class of drugs called AKT inhibitors in combination with radiotherapy might boost its effectiveness across a wide range of cancers, according to a study published in the Journal of Clinical Investigation today*. Tumours often grow so quickly that some of the cells do not have access to the body's blood supply, causing them to become oxygen-starved. This rapid growth usually sends signals to the cells to die, but in cancers with faults in a gene called p53 -- present in at least half of all cancers -- this signal ...

Article concludes no reason for laughing gas to be withdrawn from operating theaters

2015-06-01
A debate at this year's Euroanaesthesia meeting in Berlin will focus on whether laughing gas (nitrous oxide) should be banned from the operating room. The debate coincides with an article on the "Current place of nitrous oxide in clinical practice" published in the European Journal of Anaesthesiology, that concludes there is "no clinically relevant evidence for the withdrawal of nitrous oxide from the armamentarium of anaesthesia practice or procedural sedation." The article has been prepared by a special taskforce of the European Society of Anaesthesiology (ESA), which ...

American surgery patients -- more pain medication, yet more pain!

2015-06-01
New research presented at this year's Euroanaesthesia conference in Berlin shows that American patients undergoing orthopaedic surgery* receive more treatments for pain and that their experience of pain differs in some aspects to orthopaedic patients internationally. The study is by Drs Winfried Meissner and Ruth Zaslansky, University Hospital Jena, Germany, and Dr C. Richard Chapman Utah, Pain Research Center, Salt Lake City, USA. All researchers are part of the international PAIN OUT** research group. Poorly controlled pain after surgery is a major problem internationally ...

Preoperative statins reduce mortality in coronary artery bypass graft surgery

2015-06-01
Research presented at this year's Euroanaesthesia exploring the protective effect of various heart medications that patients are taking before undergoing coronary artery bypass graft (CABG) surgery concludes that statins reduce the risk of death by two thirds, or 67 percent, while no consistent effects were seen for other medications. The study is reported by Assistant Professor Dr. Robert Sanders, Anesthesiology & Critical care Trials & Interdisciplinary Outcomes Network (ACTION), Department of Anesthesiology, University of Wisconsin, Madison, WN, USA, and Drs. Puja Myles ...

Immunotherapy drug improves survival for common form of lung cancer

2015-06-01
In a head-to-head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous-non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy. Squamous non-small cell lung cancer accounts for 25 to 30 percent of all lung malignancies. Results of the trial, reported in the May 31 issue of the New England Journal of Medicine and presented at the American Society for Clinical Oncology 2015 annual meeting, also showed that after a year, the nivolumab ...

Contact lens wearers note: Your eyes may get more infections because their microbiomes changed

2015-05-31
Using high-precision genetic tests to differentiate the thousands of bacteria that make up the human microbiome, researchers at NYU Langone Medical Center suggest that they have found a possible -- and potentially surprising -- root cause of the increased frequency of certain eye infections among contact lens wearers. In a study report on their work to be presented at the annual meeting of the American Society for Microbiology on May 31 in New Orleans, NYU Langone researchers say they have identified a diverse set of microorganisms in the eyes of daily contact lens wearers ...

Immunotherapy combo increases progression-free survival in advanced melanoma patients

2015-05-31
CHICAGO, IL, MAY 31, 2015 -- Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each ...

Removing more breast tissue reduces by half the need for second cancer surgery

2015-05-30
New Haven, Conn. -- Removing more tissue during a partial mastectomy could spare thousands of breast cancer patients a second surgery, according to a Yale Cancer Center study. The findings were published online May 30 in the New England Journal of Medicine and presented at the 2015 Annual Meeting of the American Society of Clinical Oncology in Chicago. Nearly 300,000 women in the United States are diagnosed with breast cancer each year; more than half undergo breast-conserving surgery with a partial mastectomy to remove the disease. However, between 20% and 40% of patients ...

Targeted drug can 'diminish the suffering' of myelofibrosis say Mayo Clinic researchers

2015-05-30
CHICAGO -- Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent. Investigators further found that pacritinib could be used safely in patients with myelofibrosis who ...

Combining targeted drug with chemotherapy offers longer life to b-cell cancer patients

2015-05-30
CHICAGO -- Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial. Led by Mayo Clinic, researchers found that ibrutinib and chemotherapy (bendamustine and rituximab, known as BR) reduced the risk of death or cancer progression by almost 80 percent in patients with previously treated CLL or SLL, compared to use of BR alone. The announcement was made at ...

LAST 30 PRESS RELEASES:

How your brain decides blame and punishment -- and how it can be changed

Uniquely human brain region enables punishment decisions

Pinpointing punishment

Chapman University publishes research on attractiveness and mating

E-cigarettes: Special issue from Nicotine & Tobacco Research

Placental problems in early pregnancy associated with 5-fold increased risk of OB & fetal disorders

UT study: Invasive brood parasites a threat to native bird species

Criminals acquire guns through social connections

Restoring ocean health

Report: Cancer remains leading cause of death in US Hispanics

Twin study suggests genetic factors contribute to insomnia in adults

To be fragrant or not: Why do some male hairstreak butterflies lack scent organs?

International team discovers natural defense against HIV

Bolivian biodiversity observatory takes its first steps

Choice of college major influences lifetime earnings more than simply getting a degree

Dominant strain of drug-resistant MRSA decreases in hospitals, but persists in community

Synthetic biology needs robust safety mechanisms before real world application

US defense agencies increase investment in federal synthetic biology research

Robots help to map England's only deep-water Marine Conservation Zone

Mayo researchers identify protein -- may predict who will respond to PD-1 immunotherapy for melanoma

How much water do US fracking operations really use?

New approach to mammograms could improve reliability

The influence of citizen science grows despite some resistance

Unlocking secrets of how fossils form

What happens on the molecular level when smog gets into the lungs?

Using ultrasound to clean medical instruments

Platinum and iron oxide working together get the job done

Tiny silica particles could be used to repair damaged teeth, research shows

A quantum lab for everyone

No way? Charity's logo may influence perception of food in package

[Press-News.org] WSU researchers see link between hunter-gatherer cannabis use, fewer parasites
Study suggests unconscious use of 'medical marijuana'
Press-News.org is a service of DragonFly Company. All Rights Reserved.
Issuers of news releases are solely responsible for the accuracy of their content.